HONG KONG SAR - EQS Newswire - 30 December 2025 - Uni-Bio Science Group Limited ("Uni-Bio Science Group", "Uni-Bio" or "the ...
Triple-negative breast cancer (TNBC) is among the most aggressive breast cancer subtypes, with high metastasis and recurrence rates, as well as poor survival. While various molecular targets for TNBC ...
Investigators led by Navdeep Chandel, Ph.D., the David W. Cugell, MD, Professor of Medicine in the Division of Pulmonary and Critical Care, have discovered how the metabolism of mitochondria supports ...
Generation Bio announces new programs using ctLNP for targeted siRNA delivery in T cell-driven autoimmune diseases, aiming for IND submission in 2026. Development of novel siRNA therapeutics using ...
New Study Reveals How the C/G Fusion Hijacks DNA Methylation and Chromatin Architecture to Drive Aggressive AMKL Pediatric ...
Coronary artery bypass graft (CABG) surgery remains the gold standard treatment for patients with severe atherosclerosis, but the long-term failure of the grafted veins is a persistent challenge.
Climb Bio licenses CLYM116, an anti-APRIL antibody, expanding its immune-mediated disease pipeline, with preclinical data expected in 2025. Climb Bio, Inc. has announced an exclusive licensing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback